1 |
NCT00527566 |
Completed Has Results |
Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome |
|
|
Interventional |
Phase 1 Phase 2 |
- Brigham and Women's Hospital
- GlaxoSmithKline
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Indicated Side Effects
- Number of Participants Who Experienced Specific Symptoms
- Steroid Dosing During Trial
- (and 2 more...)
|
10 |
All |
19 Years and older (Adult, Senior) |
NCT00527566 |
2007-P-000012/1;BWH |
MATOCSS |
September 2007 |
August 2009 |
August 2009 |
September 11, 2007 |
March 22, 2017 |
March 22, 2017 |
- Brigham and Women's Hospital
Boston, Massachusetts, United States
|
2 |
NCT02728271 |
Terminated |
Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome |
|
- Biological: HPC cell infusion
|
Interventional |
Early Phase 1 |
- Mounzer Agha
- University of Pittsburgh
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- number of patients with adverse events during treatment
- hematologic recovery
- graft failure rate
- resolution of eosinophilia
|
1 |
All |
18 Years to 60 Years (Adult) |
NCT02728271 |
15-146 |
|
April 2016 |
July 22, 2016 |
August 20, 2016 |
April 5, 2016 |
August 1, 2017 |
|
|
3 |
NCT00399399 |
Unknown † |
CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors |
|
- Drug: azathioprine
- Drug: cyclophosphamide
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of events (failures, relapses and/or deaths) occurring in each group, defining the disease-free survival rate, measured at study end (mean follow-up of 5 years)
- Overall survival, relapse rate and adverse events, measured at study end (mean follow-up of 5 years)
|
72 |
All |
15 Years to 90 Years (Child, Adult, Senior) |
NCT00399399 |
95.067 |
|
July 1996 |
|
|
November 14, 2006 |
November 14, 2006 |
|
- Camillo Ribi
Geneva, Switzerland
|
4 |
NCT00716651 |
Completed |
Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome |
|
|
Interventional |
Phase 2 |
- University of Schleswig-Holstein
- GlaxoSmithKline
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary endpoint is the percentage of patients with Churg-Strauss Syndrome that attain remission
- Change in BVAS score
- Change in Disease Extent Index score
- (and 7 more...)
|
10 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00716651 |
RBB1 EudraCT 2006-001791-20 |
MEPOCHUSS |
July 2008 |
July 2010 |
|
July 16, 2008 |
June 15, 2012 |
|
- University Hospital Schleswig Holstein, Rheumaklinik Bad Bramstetd
Bad Bramstedt, SH, Germany
|
5 |
NCT00424749 |
Terminated Has Results |
Rituxan in Churg Strauss Syndrome With Renal Involvement |
|
- Drug: Rituximab
- Drug: Prednisone
|
Interventional |
Phase 2 |
- Fernando Fervenza
- Genentech, Inc.
- Biogen
- (and 2 more...)
|
Other / Industry / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Participants With Remission of Renal Disease Activity at 3 Months
- Participants With Normalization of Eosinophil Count at 6 Months
|
4 |
All |
18 Years and older (Adult, Senior) |
NCT00424749 |
06-004767 UL1RR024150 |
|
June 2007 |
July 2009 |
July 2009 |
January 22, 2007 |
December 8, 2011 |
December 8, 2011 |
- Mayo Clinic
Rochester, Minnesota, United States
|
6 |
NCT03036670 |
Recruiting |
Eosinophilic Granulomatosis With Polyangiitis Cohort |
|
|
Observational |
|
- Portsmouth Hospitals NHS Trust
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Diagnosis according to various diagnostic criteria
- Corticosteroid dose
- Immunosuppressive medication
- (and 4 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT03036670 |
PHT/2015/130 |
EGPA Cohort |
September 2016 |
November 2017 |
December 2017 |
January 30, 2017 |
September 20, 2017 |
|
- Queen Alexandra Hospital
Portsmouth, Hampshire, United Kingdom
|
7 |
NCT02020889 |
Completed Has Results |
A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis |
|
- Biological: Mepolizumab
- Drug: Placebo
|
Interventional |
Phase 3 |
- GlaxoSmithKline
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Industry / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of Participants in Each Category of Accrued Duration of Remission
- Number of Participants Who Are in Remission at 36 and 48 Weeks
- Time to First EGPA Relapse
- (and 20 more...)
|
136 |
All |
18 Years and older (Adult, Senior) |
NCT02020889 |
115921 |
|
February 5, 2014 |
September 5, 2016 |
September 5, 2016 |
December 25, 2013 |
January 31, 2018 |
January 26, 2018 |
- GSK Investigational Site
Denver, Colorado, United States - GSK Investigational Site
Bethesda, Maryland, United States - GSK Investigational Site
Boston, Massachusetts, United States - (and 29 more...)
|
8 |
NCT03298061 |
Active, not recruiting |
Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 |
|
- Drug: Mepolizumab
- Drug: Prednisolone
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of subjects with corticosteroid use
- Number of subjects with adverse events (AEs) and serious adverse events (SAEs)
|
119 |
All |
18 Years and older (Adult, Senior) |
NCT03298061 |
116841 |
|
April 14, 2015 |
September 7, 2018 |
September 7, 2018 |
September 29, 2017 |
October 25, 2017 |
|
- GSK Investigational Site
La Jolla, California, United States - GSK Investigational Site
Denver, Colorado, United States - GSK Investigational Site
Bethesda, Maryland, United States - (and 29 more...)
|
9 |
NCT00315380 |
Recruiting |
Determining Disease Activity Biomarkers in Individuals With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) |
- Eosinophilic Granulomatosis With Polyangiitis
- Churg-Strauss Syndrome
|
|
Observational |
|
- University of Pennsylvania
- Office of Rare Diseases (ORD)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Rare Diseases Clinical Research Network
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Discover biomarkers in EGPA capable of measuring disease activity and response to treatment
- Measure the predictive value of biomarkers for clinical outcome in EGPA
|
500 |
All |
Child, Adult, Senior |
NCT00315380 |
VCRC5506 U54AR057319 |
|
April 2006 |
April 2019 |
April 2019 |
April 18, 2006 |
January 23, 2018 |
|
- Boston University School of Medicine
Boston, Massachusetts, United States - Mayo Clinic
Rochester, Minnesota, United States - Cleveland Clinic Foundation
Cleveland, Ohio, United States - (and 5 more...)
|
10 |
NCT02807103 |
Recruiting |
Rituximab in Eosinophilic Granulomatosis With Polyangiitis |
- Eosinophilic Granulomatosis With Polyangiitis (EGPA)
|
- Drug: Rituximab
- Drug: Placebo-rituximab
- Drug: Cyclophosphamide
- Drug: Placebo-cyclophosphamide
|
Interventional |
Phase 3 |
- Assistance Publique - Hôpitaux de Paris
- French Vasculitis Study Group (FVSG)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of patients in complete remission (defined by a Birmingham Vasculitis Activity Score (BVAS) of 0 and a prednisone dose ≤7.5 mg/day )
- Number of adverse events
- Area under the curve for corticosteroids
- (and 4 more...)
|
108 |
All |
18 Years and older (Adult, Senior) |
NCT02807103 |
P140915 2016-000275-25 |
REOVAS |
December 5, 2016 |
December 2019 |
June 2020 |
June 21, 2016 |
March 19, 2018 |
|
- Hôpital Cochin
Paris, France
|
11 |
NCT03164473 |
Recruiting |
Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. |
- Eosinophilic Granulomatosis With Polyangiitis
|
- Drug: Rituximab
- Drug: Azathioprine
- Drug: Placebo-rituximab
- Drug: Placebo-azathioprine
|
Interventional |
Phase 4 |
- Assistance Publique - Hôpitaux de Paris
- French Vasculitis Study Group
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Duration of remission in weeks
- proportion of patients remaining in remission with a BVAS=0 and prednisone dose ≤7.5 mg/day
- proportion of patients remaining in remission with a BVAS=0
- (and 14 more...)
|
98 |
All |
18 Years and older (Adult, Senior) |
NCT03164473 |
P150922 2016-000627-53 |
MAINRITSEG |
March 7, 2018 |
July 2022 |
July 2022 |
May 23, 2017 |
March 19, 2018 |
|
- Hôpital Cochin
Paris, France
|
12 |
NCT00647166 |
Completed |
Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) |
- MPA
- PAN or EGPA With FFS=0
- At Diagnosis or Within the First 15 Days Following Initiation of Corticosteroids
|
- Drug: corticosteroid and azathioprine
- Drug: corticosteroid and placebo
|
Interventional |
Phase 3 |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- combined rate of remission-treatment failures and minor or major relapses at 24 months
- initial remission rate (independently of subsequent relapse)
- number of patients who have a minor or major relapse
- (and 8 more...)
|
114 |
All |
18 Years and older (Adult, Senior) |
NCT00647166 |
P 060243 |
CHUSPAN2 |
May 2008 |
March 2015 |
April 2015 |
March 31, 2008 |
October 7, 2015 |
|
- Hopital Cochin Pôle de Médecine UF Médecine Interne
Paris, France
|
13 |
NCT02947945 |
Recruiting |
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study |
|
|
Interventional |
Phase 2 |
- National Jewish Health
- TEVA
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Document the safety of reslizumab therapy in patients with EGPA
- Demonstrate the steroid sparing effect of reslizumab therapy by titrating corticosteroid dosage
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT02947945 |
HS-3025 |
RITE |
September 12, 2017 |
December 2018 |
December 2018 |
October 28, 2016 |
September 14, 2017 |
|
- National Jewish Health
Denver, Colorado, United States
|
14 |
NCT01729624 |
Unknown † |
PRO Development for ANCA Associated Vasculitis |
- Wegener Granulomatosis
- Microscopic Polyangiitis
- Churg-Strauss Syndrome
|
|
Observational |
|
|
Other |
- Time Perspective: Prospective
|
- This is a qualitative research study based on semi-quantitive exploratory patient interviews and therefore it is not appropriate to define only one outcome measure.
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT01729624 |
Rec No: 12/SW/0252 |
|
September 2012 |
August 2015 |
August 2015 |
November 20, 2012 |
May 28, 2015 |
|
- University of Oxford
Oxford, Oxfordshire, United Kingdom
|
15 |
NCT00307593 |
Completed |
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides |
- Wegener's Granulomatosis
- Churg-Strauss Syndrome
- Microscopic Polyangiitis
|
- Drug: Infliximab
- Drug: Rituximab
|
Interventional |
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Partial or complete remission of the vasculitides
- To study the safety and adverse effects of both regimens
- Microscopic polyangiitis
- (and 2 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT00307593 |
P020931 AOM02098 |
|
May 2004 |
|
June 2007 |
March 28, 2006 |
November 19, 2007 |
|
- Hôpital Cochin
Paris, France
|
16 |
NCT03010436 |
Recruiting |
Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study |
|
|
Interventional |
Phase 2 |
- National Jewish Health
- AstraZeneca
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- All adverse events will be reported by count of events (safety and tolerability )
- Change in corticosteroid dosage
- Change in the rate of EGPA exacerbations during the study period.
|
10 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT03010436 |
HS-3010 |
BITE |
April 15, 2017 |
December 2018 |
December 2018 |
January 5, 2017 |
May 9, 2017 |
|
- National Jewish Health
Denver, Colorado, United States
|
17 |
NCT00751517 |
Unknown † |
Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides |
- Wegener's Granulomatosis
- Churg-Strauss Syndrome
- Microscopic Polyangiitis
- Polyarteritis Nodosa
|
- Drug: Methotrexate
- Drug: Cyclophosphamide
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time from remission to relapse
- Recurrence rate
- Therapy-related toxicity
- (and 2 more...)
|
|
All |
18 Years to 80 Years (Adult, Senior) |
NCT00751517 |
PCM 01 |
|
|
|
|
September 12, 2008 |
September 12, 2008 |
|
- Department of Clinical Medicine Nephrology and Health Science, Parma University Hospital
Parma, Italy/Parma, Italy
|
18 |
NCT00266565 |
Completed |
Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome |
- Hypereosinophilic Syndromes
- Eosinophilic Gastroenteritis
- Churg-Strauss Syndrome
- Eosinophilic Esophagitis
|
|
Interventional |
Phase 1 Phase 2 |
- Children's Hospital Medical Center, Cincinnati
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the toxicity of anti-IL-5 in patients with hypereosinophilia
- To assess whether anti-IL-5 lowers peripheral blood eosinophils and/or tissue in patients with hypereosinophilia
- To assess whether anti-IL-5 has a steroid and/or interferon sparing effect
|
24 |
All |
18 Years to 65 Years (Adult) |
NCT00266565 |
01-9-18 FD-R-002396 |
|
December 2001 |
July 2012 |
July 2012 |
December 19, 2005 |
January 23, 2017 |
|
- Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
|
19 |
NCT00307671 |
Completed |
Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years |
- Vasculitis
- Wegener's Granulomatosis
- Microscopic Polyangiitis
- (and 2 more...)
|
- Drug: prednisone, methylprednisolone,cyclophosphamides
- Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone
- Drug: Mycophenolate mofetil,methotrexate
|
Interventional |
Phase 4 |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of side effects (morbidity)
- Survival
- Efficacy of treatment (remission rate)
- (and 3 more...)
|
108 |
All |
65 Years and older (Adult, Senior) |
NCT00307671 |
P040425 |
CORTAGE |
July 2005 |
July 2011 |
July 2011 |
March 28, 2006 |
September 12, 2011 |
|
- Hôpital Cochin
Paris, France
|
20 |
NCT02507024 |
Completed |
The ANCA Vasculitis Questionnaire (AAV-PRO©) |
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA)
- Churg-Strauss Syndrome (CSS)
- Granulomatosis With Polyangiitis (Wegener's) (GPA)
- (and 4 more...)
|
- Other: Online questionnaire
|
Observational |
|
- University of Pennsylvania
- University of Oxford
- University of South Florida
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Completion of AAV-PRO questionnaire.
|
280 |
Female |
18 Years and older (Adult, Senior) |
NCT02507024 |
VCRC 5537 |
AAV-PRO |
July 2015 |
December 2016 |
December 2016 |
July 23, 2015 |
May 4, 2017 |
|
- University of South Florida
Tampa, Florida, United States - University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
21 |
NCT02967068 |
Recruiting |
VCRC Tissue Repository |
- Aortitis
- Cutaneous Vasculitis
- Eosinophilic Granulomatosis With Polyangiitis
- (and 8 more...)
|
|
Observational |
|
- University of Pennsylvania
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- National Center for Advancing Translational Science (NCATS)
- Office of Rare Diseases (ORD)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Other
|
- Identify genes that increase the risk of developing vasculitis
|
1000 |
All |
Child, Adult, Senior |
NCT02967068 |
VCRC5511 U54AR057319 |
|
November 2016 |
December 2019 |
December 2019 |
November 17, 2016 |
January 23, 2018 |
|
- Boston University School of Medicine
Boston, Massachusetts, United States - Cleveland Clinic
Cleveland, Ohio, United States - University of Pennsylvania
Philadelphia, Pennsylvania, United States - (and 3 more...)
|
22 |
NCT03482479 |
Not yet recruiting New |
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis |
- Eosinophilic Granulomatosis With Polyangiitis (EGPA)
- Churg-Strauss Syndrome (CSS)
- Giant Cell Arteritis
- (and 4 more...)
|
- Drug: Naltrexone Hydrochloride
- Other: Placebo Comparator
|
Interventional |
Phase 2 |
- University of Pennsylvania
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- PROMIS Global Physical Health
- SF-36 (physical component subscore)
- PROMIS Questionnaires
- (and 2 more...)
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT03482479 |
VCRC5564 |
LoDoNaVasc |
May 10, 2018 |
May 31, 2019 |
August 31, 2019 |
March 29, 2018 |
March 29, 2018 |
|
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
23 |
NCT00006055 |
Unknown † |
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases |
- Purpura, Schoenlein-Henoch
- Graft Versus Host Disease
- Anemia, Hemolytic, Autoimmune
- (and 11 more...)
|
- Drug: anti-thymocyte globulin
- Drug: cyclophosphamide
- Drug: cyclosporine
- (and 4 more...)
|
Interventional |
Not Applicable |
- Fairview University Medical Center
- Office of Rare Diseases (ORD)
|
Other |
- Primary Purpose: Treatment
|
|
10 |
All |
1 Year to 55 Years (Child, Adult) |
NCT00006055 |
199/15105 UMN-MT-1996-15 UMN-MT-9615 |
|
March 2000 |
|
|
July 6, 2000 |
June 24, 2005 |
|
- Fairview University Medical Center
Minneapolis, Minnesota, United States
|
24 |
NCT01066208 |
Recruiting |
American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis |
- Wegener's Granulomatosis
- Microscopic Polyangiitis
- Churg Strauss Syndrome
- (and 3 more...)
|
|
Observational |
|
- University of Oxford
- American College of Rheumatology
- The European League Against Rheumatism (EULAR)
- The Vasculitis foundation
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Develop new diagnostic and classification criteria for ANCA associated vasculitis and polyarteritis nodosa
|
3588 |
All |
18 Years and older (Adult, Senior) |
NCT01066208 |
ACREULAR001 |
DCVAS |
January 2011 |
December 2017 |
December 2018 |
February 10, 2010 |
August 19, 2016 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Cedars-Sinai Medical Center, LA
Los Angeles, California, United States - University of California, San Francisco
San Francisco, California, United States - (and 117 more...)
|
25 |
NCT02593565 |
Recruiting |
Vasculitis Pregnancy Registry |
- Vasculitis
- Behcet's Disease
- CNS Vasculitis
- (and 12 more...)
|
- Other: Online questionnaires
|
Observational |
|
- University of Pennsylvania
- Duke University
- University of South Florida
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Unique pregnancy characteristics among women with vasculitis.
|
100 |
Female |
18 Years to 50 Years (Adult) |
NCT02593565 |
VCRC 5532 |
V-PREG |
November 2015 |
December 2019 |
December 2019 |
November 2, 2015 |
April 28, 2017 |
|
- University of South Florida Data Management and Coordinating Center
Tampa, Florida, United States
|
26 |
NCT02006134 |
Recruiting |
Pediatric Vasculitis Initiative |
- Wegeners Granulomatosis (Granulomatosis With Polyangiitis)
- Microscopic Polyangiitis
- Churg Strauss Syndrome (Eosinophilic Granulomatosis With Polyangiitis)
- (and 4 more...)
|
|
Observational |
|
- University of British Columbia
- Canadian Institutes of Health Research (CIHR)
- Simon Fraser University
- (and 5 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Develop new benchmarks for outcome in pediatric patients with systemic or CNS vasculitis
|
1600 |
All |
up to 20 Years (Child, Adult) |
NCT02006134 |
H12-00894 TR2-119188 |
PedVas |
January 2013 |
December 2017 |
December 2018 |
December 10, 2013 |
May 3, 2017 |
|
- University of San Francisco
San Francisco, California, United States - University of Florida
Gainesville, Florida, United States - Medical College of Georgia
Augusta, Georgia, United States - (and 37 more...)
|
27 |
NCT02190942 |
Enrolling by invitation |
VCRC Patient Contact Registry Patient-Reported Data Validation Study |
- Behcet's Disease
- Churg-Strauss Syndrome
- Giant Cell Arteritis
- (and 4 more...)
|
|
Observational |
|
- University of South Florida
- Wayne State University
- University of Pittsburgh
- (and 2 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Validation of the currently utilized VCRC Patient Contact Registry Questionnaire
- Evaluate diagnostic accuracy of specific questions
|
140 |
All |
Child, Adult, Senior |
NCT02190942 |
5535 |
|
May 2014 |
July 2019 |
July 2019 |
July 15, 2014 |
October 18, 2017 |
|
- University of South Florida Data Management Coordinating Center
Tampa, Florida, United States
|
28 |
NCT02190929 |
Completed |
Educational Needs of Patients With Systemic Vasculitis |
- Behcet's Disease
- Churg-Strauss Syndrome
- Vasculitis, Central Nervous System
- (and 6 more...)
|
|
Observational |
|
- University of South Florida
- Boston University
- University of Pennsylvania
- Data Management and Coordinating Center (DMCC)
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Preferred method and component of education materials for patients with vasculitis
|
386 |
All |
18 Years and older (Adult, Senior) |
NCT02190929 |
5534 |
|
March 2012 |
February 2014 |
February 2014 |
July 15, 2014 |
July 15, 2014 |
|
- University of South Florida Data Management Coordinating Center
Tampa, Florida, United States
|
29 |
NCT02190916 |
Completed |
Vasculitis Illness Perception (VIP) Study |
- Wegener Granulomatosis
- Microscopic Polyangiitis
- Churg-Strauss Syndrome
- (and 6 more...)
|
|
Observational |
|
- University of South Florida
- Boston University
- Yale University
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Composite measure to include Illness perceptions, fatigue and function in patients with systemic vasculitis with further emphasis on causal beliefs about disease onset and relapse triggers.
- Composite measure of potential associations between illness perceptions, fatigue and function in patients with systemic vasculitis
|
707 |
All |
18 Years and older (Adult, Senior) |
NCT02190916 |
5533 |
|
October 2011 |
October 2013 |
October 2013 |
July 15, 2014 |
July 15, 2014 |
|
- University of South Florida Data Management Coordinating Center
Tampa, Florida, United States
|
30 |
NCT02176070 |
Completed |
Reproductive Health in Men and Women With Vasculitis |
- Giant Cell Arteritis
- Takayasu's Arteritis
- Polyarteritis Nodosa
- (and 8 more...)
|
|
Observational |
|
- University of South Florida
- Duke University
- Boston University
- Data Management and Coordinating Center (DMCC)
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- The rate of infertility with and without prior cyc.
- The rate of pregnancy complications in pregnancies delivered before and after vasculitis diagnosis.
|
467 |
All |
18 Years and older (Adult, Senior) |
NCT02176070 |
5531 |
|
February 2011 |
March 2012 |
March 2012 |
June 26, 2014 |
June 26, 2014 |
|
- University of South Florida Data Management Coordinating Center
Tampa, Florida, United States
|
31 |
NCT01241305 |
Recruiting |
One-Time DNA Study for Vasculitis |
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
- Giant Cell Arteritis
- Granulomatosis With Polyangiitis (Wegener's)
- (and 3 more...)
|
|
Observational |
|
- University of Pennsylvania
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Office of Rare Diseases (ORD)
- Rare Diseases Clinical Research Network
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Evaluation of clinical data and linked DNA specimens.
|
1300 |
All |
7 Years and older (Child, Adult, Senior) |
NCT01241305 |
VCRC5510 U54AR057319-06 |
|
October 2010 |
August 2018 |
August 2018 |
November 16, 2010 |
January 23, 2018 |
|
- Cedars-Sinai Medical Center
Los Angeles, California, United States - University of California, San Francisco
San Francisco, California, United States - University of Kansas Medical Center
Kansas City, Kansas, United States - (and 11 more...)
|
32 |
NCT03410290 |
Recruiting |
Journey of Patients With Vasculitis From First Symptom to Diagnosis |
- Vasculitis
- Systemic Vasculitis
- Behcet's Disease
- (and 13 more...)
|
- Other: Online Questionnaire
|
Observational |
|
- University of Pennsylvania
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentages of patients with different types of vasculitis who report a delay in their disease diagnosis from initial symptoms of vasculitis to establishment of a diagnosis of vasculitis, stratified by disease type.
|
400 |
All |
Child, Adult, Senior |
NCT03410290 |
VCRC5538/V-PPRN4 |
|
January 11, 2018 |
January 31, 2019 |
February 28, 2019 |
January 25, 2018 |
January 25, 2018 |
|
- University of South Florida
Tampa, Florida, United States
|
33 |
NCT03004326 |
Recruiting |
Clinical Transcriptomics in Systemic Vasculitis (CUTIS) |
- Cryoglobulinemic Vasculitis (CV)
- Drug-induced Vasculitis
- Eosinophilic Granulomatosis With Polyangiitis (EGPA)
- (and 7 more...)
|
|
Observational |
|
- Peter Merkel
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- National Center for Advancing Translational Science (NCATS)
- (and 2 more...)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Evaluation of clinical data and linked biopsy specimens
|
50 |
All |
5 Years and older (Child, Adult, Senior) |
NCT03004326 |
VCRC5563 U54AR057319 |
CUTIS |
January 2017 |
August 2019 |
August 2019 |
December 28, 2016 |
April 11, 2018 |
|
- University of California, Los Angeles
Los Angeles, California, United States - Boston University School of Medicine
Boston, Massachusetts, United States - Mayo Clinic
Rochester, Minnesota, United States - (and 4 more...)
|
34 |
NCT00482066 |
Terminated |
Abatacept in ANCA Associated Vasculitis |
- ANCA-associated Vasculitis
|
- Drug: Abatacept (Orencia)
|
Interventional |
Phase 2 |
- Imperial College London
- Bristol-Myers Squibb
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Relapse rate over 24 months.
- Proportion of patients in sustained remission (i.e. remission at 3 months sustained for 6 months and remission at 6 months sustained for a further 12 months);
- Time to remission;
- (and 6 more...)
|
7 |
All |
18 Years and older (Adult, Senior) |
NCT00482066 |
cro632 2006-001859-35 BMS protocol No: IST110 |
ABAVAS |
November 2007 |
November 2008 |
November 2008 |
June 4, 2007 |
May 29, 2015 |
|
- Imperial College London, Hammersmith Hospital
London, United Kingdom
|